Who is the manufacturer of Xenograft Bovine Bone Particulate?

Collagen Solutions, LLC filed the 510(k) submission for Xenograft Bovine Bone Particulate (K240133).

What is the FDA product code for Xenograft Bovine Bone Particulate?

NPM. It is classified under 21 CFR 872.3930 as a Class 2 device in the Dental panel.

What is the regulatory pathway for Xenograft Bovine Bone Particulate?

510(k) clearance (submission type: Traditional).

What are the predicate devices for Xenograft Bovine Bone Particulate?

Collagen Matrix OsteoGuide™ Anorganic Bone Mineral (K043034).

Who can help prepare an FDA 510(k) submission like Xenograft Bovine Bone Particulate?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

Xenograft Bovine Bone Particulate

K240133 · Collagen Solutions, LLC · NPM · Aug 16, 2024 · Dental

Device Facts

Record ID	K240133
Device Name	Xenograft Bovine Bone Particulate
Applicant	Collagen Solutions, LLC
Product Code	NPM · Dental
Decision Date	Aug 16, 2024
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 872.3930
Device Class	Class 2
Attributes	Therapeutic

Intended Use

Xenograft Bovine Bone Particulate is intended for use in dental surgery. The products may be used in surgical procedures such as: Augmentation or reconstructive treatment of alveolar ridge Filling of periodontal defects Filling of defects after root resection, apicocectomy, and cystectomy Filling of extraction sockets to enhance preservation of the alveolar ridge Elevation of maxillary sinus floor Filling of defects in conjunction with products intended for Guided Bone Regeneration (GBR) Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR)

Device Story

Xenograft Bovine Bone Particulate is a porous, trabecular bone mineral matrix derived from bovine sources; used as a scaffold for new bone formation in dental, oral, and maxillofacial surgical procedures. Dentists manually pack the particulate granules into osseous defects using sterile instruments. The device provides a structural framework that supports the ingrowth of new bone; it is resorbed over time (>6 months). Used in clinical dental settings; the device benefits patients by facilitating bone regeneration in various dental defects and extraction sites.

Clinical Evidence

Bench testing confirmed compliance with ASTM F1581 and ISO 10993 biocompatibility standards. In-vivo performance was evaluated in a beagle mandibular intraoral critical size defect model, comparing the subject device to the predicate and a negative control. Histomorphometry and histopathology assessments at 4, 12, and 24 weeks demonstrated substantial equivalence in new bone formation, residual graft material, and tissue reaction.

Technological Characteristics

Anorganic bovine bone mineral; trabecular architecture with interconnected macro/micro pores. Complies with ASTM F1581-08. Available in various granule sizes (cancellous and cortical). Sterilized via electron beam irradiation (SAL 10^-6). Biocompatibility per ISO 10993-1.

Indications for Use

Indicated for patients requiring dental surgery for alveolar ridge augmentation, periodontal defect repair, root resection/apicocectomy/cystectomy defect filling, extraction socket preservation, maxillary sinus floor elevation, or peri-implant defect filling in conjunction with GBR.

Regulatory Classification

Identification

Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.

Special Controls

*Classification.* (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

Collagen Matrix OsteoGuide™ Anorganic Bone Mineral (K043034)

Related Devices

K251613 — SwissGraft X · Geistlich Pharma AG · Jun 26, 2025
K970321 — BIO-OSS ANORGANIC BOVINE BONE · Geistlich-Pharma · Sep 15, 1998
K170245 — DSM Biomedical Dental Bone Graft · Kensey Nash Corporation Dba Dsm Biomedical · May 16, 2017
K122894 — GEISTLICH BIO-OSS, GEISTLICH BIO-OSS COLLAGEN, GEISTLICH COMBI-KIT COLLAGEN, GEISTLICH PERIO SYSTEM COMBI PACK, GEISTLIC · Geistlich Pharma AG · Feb 15, 2013
K193212 — DSM Biomedical Dental Bone Graft Plus · Dsm Biomedical · Sep 10, 2020

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. August 16, 2024 Collagen Solutions, LLC % Richelle Helman Senior Director, Regulatory MEDIcept Inc. 200 Homer Avenue Ashland, Massachusetts 01721 Re: K240133 Trade/Device Name: Xenograft Bovine Bone Particulate Regulation Number: 21 CFR 872.3930 Regulation Name: Bone Grafting Material Regulatory Class: Class II Product Code: NPM Dated: January 16, 2024 Received: July 22, 2024 Dear Richelle Helman: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products: and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. {2}------------------------------------------------ For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Sherrill Lathrop Blitzer for Andrew Steen Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # Indications for Use 510(k) Number (if known) K240133 Device Name Xenograft Bovine Bone Particulate #### Indications for Use (Describe) Xenograft Bovine Bone Particulate is intended for use in dental surgery. The products may be used in surgical procedures such as: * Augmentation or reconstructive treatment of alveolar ridge - * Filling of periodontal defects - * Filling of defects after root resection, apicocectomy, and cystectomy - * Filling of extraction sockets to enhance preservation of the alveolar ridge - * Elevation of maxillary sinus floor - * Filling of defects in conjunction with products intended for Guided Bone Regeneration (GBR) - * Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR) | Type of Use (Select one or both, as applicable) | | |-------------------------------------------------|--| |-------------------------------------------------|--| X Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4}------------------------------------------------ Image /page/4/Picture/0 description: The image is a logo for Collagen Solutions. The logo has a graphic on the left side that consists of three overlapping wavy lines in red, green, and blue. To the right of the graphic is the text "COLLAGEN SOLUTIONS" in a dark gray sans-serif font. Below the text is the phrase "MATERIALS FOR LIFE" in a smaller, lighter gray font. | Date: | 15-August-2024 | |----------------------------|----------------------------------------------------------------------------------------------| | Company: | Collagen Solutions 6455 City West Pkwy Eden Prairie, MN 55344 Phone: (320) 510-3615 | | Applicant Contact: | Sheila Hunter Vice President of Quality and Regulatory Affairs | | Official Contact: | Richelle Helman Senior Director, Regulatory | | Proprietary or Trade Name: | Xenograft Bovine Bone Particulate | | Common/Usual Name: | Bone Grafting Material | | Classification Name: | Bone Grafting Material, Animal Source | | Regulation Number: | 21 CFR 872.3930 Classification Product Code: NPM | | Predicate Device: | K043034: Collagen Matrix OsteoGuide™ Anorganic Bone Mineral | ### Device Description: The Xenograft Bovine Bone Particulate is a porous bone mineral matrix that is used in periodontal, oral, and maxillofacial surgery. It has a trabecular architecture, interconnecting macro and micro pores and consistency which allows formation and ingrowth of new bone. The particulate is available in clinically relevant sizes. The anorganic bone composition meets all requirements found in ASTM 1581-08: Standard Specification for Composition of Anorganic Bone for Surgical Implants. The device is packaged, and electron beam irradiated to meet all requirements and is non-pyrogenic. Using standard dental techniques, the dentist will loosely pack the xenograft particulate granules into the osseous defect using sterile instruments. ### Indications for Use: Xenograft Bovine Bone Particulate is intended for use in dental surgery. The products may be used in surgical procedures such as: - Augmentation or reconstructive treatment of alveolar ridge ● - . Filling of periodontal defects - Filling of defects after root resection, apicocectomy, and cystectomy - . Filling of extraction sockets to enhance preservation of the alveolar ridge - Elevation of maxillary sinus floor - Filling of periodontal defects in conjunction with products intended for Guided Bone Regeneration (GBR) - Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR) {5}------------------------------------------------ Image /page/5/Picture/0 description: The image is a logo for Collagen Solutions. The logo has a graphic of three overlapping sine waves in red, green, and blue. To the right of the graphic is the text "COLLAGEN SOLUTIONS" in a dark gray sans-serif font, with the words "MATERIALS FOR LIFE" in a smaller, lighter gray font underneath. ## Substantial Equivalence: The Collagen Solutions Xenograft Bovine Bone Particulate is substantially equivalent to the predicate device, the Collagen Matrix OsteoGuide™ Anorganic Bone Mineral (510(k) K043034). The table below presents the similarities and differences between the products for substantial equivalence purposes. The difference between the subject device and the predicate device does not raise any new issues of safety and effectiveness. Performance data are available to support substantial equivalence. | Characteristic | Subject Device: | Predicate Device: | Substantial | |--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------| | | Collagen Solutions Xenograft Bovine Bone Particulate | Collagen Matrix, Inc. OsteoGuide Anorganic Bone Mineral [510(k) K043034] | Equivalence | | Indications for Use | Xenograft Bovine Bone Particulate is intended for use in dental surgery. The products may be used in surgical procedures such as: * Augmentation or reconstructive treatment of alveolar ridge * Filling of periodontal defects * Filling of defects after root resection, apicocectomy, and cystectomy * Filling of extraction sockets to enhance preservation of the alveolar ridge * Elevation of maxillary sinus floor * Filling of periodontal defects in conjunction with products intended for Guided Bone Regeneration (GBR) * Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration (GBR) | Natural Anorganic Bone Graft Substitutes are intended for use in dental surgery. The products may be used in surgical procedures such as: * Augmentation or reconstructive treatment of alveolar ridge * Filling of periodontal defects * Filling of defects after root resection, apicocectomy, and cystectomy * Filling of extraction sockets to enhance preservation of the alveolar ridge * Elevation of maxillary sinus floor * Filling of periodontal defects in conjunction with products intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR) * Filling of peri-implant defects in conjunction with products intended for Guided Bone Regeneration | SAME | | Physical Form | Ground bone particulate in a dappen dish | Ground bone particulate in a dappen dish | SAME | | Color | White to off-white | White to off-white | SAME | | Material composition | Anorganic bovine bone mineral | Anorganic bovine bone mineral | SAME | | Characteristic | Subject Device: Collagen Solutions Xenograft Bovine Bone Particulate | Predicate Device: Collagen Matrix, Inc. OsteoGuide Anorganic Bone Mineral [510(k) K043034] | Substantial Equivalence | | Size (Dimension and weight) | Small Cancellous Granules (0.25-1mm): 0.25g/0.6cc, 0.5g/1.2cc, 1.0g/2.4 cc, 1.25g/3.0 cc, 2.0 g/4.7 cc Large Cancellous (1-2 mm): 0.25g/0.85cc, 0.5g/1.7cc, 1.0g/3.4 cc, 1.2g/4.0 cc, 2.0 g/6.8 cc Cortical Bone (0.5-1 mm): 0.25g/0.4 cc, 0.5g/0.8cc, 1.0g/1.6 cc, 1.25g/2.0 cc, 2.0 g/3.2 cc | Small Cancellous Granules (0.25-1mm): 0.25g/0.6cc, 0.5g/1.2cc, 1.0g/2.4 cc, 2.0 g/4.7 cc Large Cancellous (1-2 mm): 0.25g/0.85cc; 0.5g/1.7cc, 1.0g/3.4 cc; 2.0 g/6.8 cc Cortical Bone (0.5-1 mm): 0.25g/0.4cc, 0.5g/0.8cc, 1.0g/1.6 cc, 2.0 g/3.2 cc | SIMILAR The subject device has one additional size in each bone type that is within the range of sizes available in the predicate device. | | Source of bone | Bovine | Bovine | SAME | | Physical morphology | Trabecular, interconnected macro and micro pores | Trabecular, interconnected macro and micro pores | SAME | | Crystallinity | 83-98% | 83-98% | SAME | | Calcium Phosphate Ratio | 2.3-2.5 | 2.3-2.5 | SAME | | Resorption Time | > 6 months | > 6 months | SAME | | Performance | Bone formation | Bone formation | SAME | | FDA Recognized Standards | ASTM F1581 ISO 10993-1 | ASTM F1581 ISO 10993-1 | SAME | {6}------------------------------------------------ Image /page/6/Picture/0 description: The image is a logo for Collagen Solutions. The logo has an abstract design on the left side with three overlapping curved lines in red, green, and blue. To the right of the design is the text "COLLAGEN SOLUTIONS" in a bold, sans-serif font. Below that is the text "MATERIALS FOR LIFE" in a smaller, lighter font. From the comparison form above, the subject device and predicate device have the same intended use and the same operating principle for acting as a scaffold for new bone formation in dental surgery. The minor difference in the additional sizes offered does not raise different questions of safety or effectiveness. ## Non-clinical performance testing: Bench / Performance Testing - - . Bench testing was conducted in order to demonstrate that Collagen Solutions Xenograft Bovine Bone Particulates perform according to its requirements and specifications. In particular, the composition of the Collagen Solutions Xenograft Bovine Bone Particulates meets the requirements of ASTM F1581 "Standard Specification for Composition of Anorganic Bone for Surgical Implants". - Apparent Density - Ca/P ratio {7}------------------------------------------------ Image /page/7/Picture/0 description: The image shows the logo for Collagen Solutions. The logo consists of three overlapping, wavy lines in red, green, and blue, with a series of blue circles above them. To the right of the lines, the words "COLLAGEN SOLUTIONS" are written in a bold, sans-serif font, with the words "MATERIALS FOR LIFE" written in a smaller font below. - Crystallinity - Protein Content - Heavy metal - Biocompatibility was evaluated in accordance with ISO 10993-1 as follows: - Cytotoxicity per ISO 10993-5 - Irritation per ISO 10093-10 - Sensitization per ISO 10993-10 - Genotoxicity per ISO 10993-3 - Acute systemic toxicity per ISO 10993-11 - Subchronic toxicity per ISO 10993-11 - Implantation per ISO 10993-6 - Pyrogenicity per ISO 10993-11 and endotoxin testing (LAL, Limulus Amebocyte Lysate) per USP <85> All tests indicated the patient contact materials were biocompatible. - The product is radiation sterilized. Sterilization process validation was performed in . accordance with the ANSI/AAMI/ISO 11137 series demonstrating a Sterility Assurance Level (SAL) of 10-6. The in-vivo performance of the subject device in a beagle mandibular intraoral critical size defect model was compared to that of the primary predicate device, Collagen Matrix OsteoGuide™ Anorqanic Bone Mineral. New bone formation, presence of residual graft material and tissue reaction were assessed by histomorphometry and histopathology, at 4, 12 and 24 weeks for the subject device, primary predicate device and neqative control. The results demonstrated that the performance of the subject and primary predicate devices was substantially equivalent. The results demonstrated that the Collagen Solutions Xenograft Bovine Bone Particulates performs according to its specifications and functions as intended. ### Substantial Equivalence Conclusion Performance testing demonstrated that any risks associated with the subject device do not raise any new questions of substantial equivalence. The minor difference in sizes offered does not raise different questions of substantial equivalence based on the performance data. The use of the Collagen Solutions Xenograft Bovine Bone Particulates is substantially equivalent to the predicate device.